10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.

      Leukemia Research
      Amsacrine, pharmacology, Antineoplastic Agents, Digitoxin, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Etoposide, antagonists & inhibitors, Humans, Idarubicin, K562 Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, drug therapy, Mitoxantrone, Structure-Activity Relationship, Topoisomerase II Inhibitors

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Digitoxin is used in the treatment of cardiac congestion and some types of cardiac arrhythmias. The mechanism of action of this cardiac glycoside suggested that it might antagonize the anticancer activity of topoisomerase II poisons. The present report shows that digitoxin, at concentrations commonly found in the plasma of cardiac patients, significantly reduced etoposide and idarubicin-induced topoisomerase II cleavable complexes in K562 leukemia cells. This may lead to a reduction in the anticancer effect of these two topoisomerase II poisons when they are used in the clinic concurrently with digitoxin.

          Related collections

          Author and article information

          Comments

          Comment on this article